A recent ruling by Turkey’s Court of Cassation (Yargıtay) is reshaping the landscape of access to innovative, often life-saving, “smart” drugs for cancer patients. The decision, reported on March 14, 2026, effectively ends a period where patients could successfully sue the Social Security Institution (SGK) for reimbursement of expensive medications simply by presenting a doctor’s prescription. The court now mandates that patients must demonstrate, through robust scientific and medical evidence, that a particular drug is appropriate and beneficial for their specific condition before the SGK is obligated to cover the cost. This shift has significant implications for both patients and the Turkish healthcare system, raising questions about access to cutting-edge treatments and the sustainable allocation of public funds.
The ruling stems from a case involving a cancer patient seeking coverage for an “intelligent” drug – a term commonly used in Turkey to refer to targeted therapies and immunotherapies – not included on the SGK’s reimbursement list. According to assessments by İsa Karakaş, a former chief inspector for the SGK, the previous practice allowed patients to pursue legal action with the expectation of success, relying on a doctor’s report as sufficient justification for reimbursement. Karakaş stated, as reported by *Finans.mynet.com*, that the era of “I will pay for the smart drug myself, then win the case in court based on the treatment report and get my money back” is now over. This suggests a significant change in the legal precedent surrounding access to these medications.
The Case of Avelumab and Lower Court Decisions
The Yargıtay’s decision overturned previous rulings in a specific case involving Avelumab, an immunotherapy drug used in the treatment of certain cancers. The patient had filed a lawsuit against the SGK seeking coverage for the medication. Both the initial court and the Regional Court of Appeal (Bölge Adliye Mahkemesi – İstinaf) sided with the patient, deeming the doctor’s report sufficient grounds for the SGK to cover the drug’s cost. Though, the Yargıtay found that the lower courts had not conducted a thorough enough examination of the case and reversed their decision, emphasizing the need for more comprehensive scientific criteria to justify reimbursement.
Yargıtay’s Reasoning: Balancing Healthcare Access and Fiscal Responsibility
The Yargıtay’s 10th Chamber of Law grounded its decision in the delicate balance between a citizen’s right to healthcare and the state’s financial obligations. The court referenced rulings from the European Court of Human Rights (AİHM), acknowledging that while universal access to healthcare is desirable, it is inextricably linked to the availability of state resources. The court reasoned that an unrestricted obligation to cover the cost of every medication could jeopardize the SGK’s ability to provide a minimum level of sustainable healthcare to the entire population.
To clarify the criteria for reimbursement, the Yargıtay established what it termed “golden criteria” that courts must now consider when evaluating requests for coverage of innovative drugs. These criteria include:
- Completed Phase Trials: The drug’s reliability and efficacy must be established and registered globally and within Turkey.
- Personalized Suitability: Genetic testing must be conducted to determine the drug’s appropriateness for the individual patient.
- Sustained Benefit: A medical board must report that the drug is expected to provide continuous improvement for the patient.
- Failure of Standard Treatment: It must be proven that the SGK’s currently covered treatments are inadequate for the patient’s condition.
Implications for Patients and the SGK
This ruling signals the end of an era where the expectation was that “every recent drug will be paid for every patient.” Patients seeking coverage for innovative medications will now be required to provide medical documentation demonstrating the drug’s suitability based on their genetic makeup and specific medical profile *before* initiating legal action. This represents a significant shift in the burden of proof, placing greater responsibility on patients and their physicians to justify the need for these often-expensive treatments.
the decision aims to promote the efficient employ of limited public resources by preventing uncontrolled spending on drugs with weak scientific foundations or those still in the experimental phase. The Yargıtay’s ruling provides a roadmap for patients awaiting access to smart drugs, emphasizing that while the right to life is paramount, treatments must be supported by both medical necessity and scientific evidence to qualify for public funding. Karakaş concluded, as reported by *Finans.mynet.com*, that “Yes, the right to life is sacred; however, no treatment unsupported by medical necessity and scientific data can be imposed on the public (SGK) budget.”
The decision also comes amidst broader concerns about the financial sustainability of the Turkish healthcare system. According to data from the Turkish Statistical Institute (TurkStat), healthcare expenditure as a percentage of GDP has been steadily increasing in recent years, placing strain on public finances. The World Bank reports that Turkey’s health expenditure as a percentage of GDP was 6.4% in 2022, up from 5.4% in 2015. This context underscores the Yargıtay’s emphasis on responsible resource allocation.
The Role of İsa Karakaş in the Debate
İsa Karakaş, the former SGK chief inspector whose analysis has been central to reporting on this ruling, has been a vocal commentator on issues related to social security and healthcare financing in Turkey. His columns in *Türkiye Gazetesi* frequently address challenges facing the SGK and propose solutions for improving the efficiency and sustainability of the system. Karakaş’s insights are often sought by media outlets covering healthcare policy in Turkey, and his perspective is considered influential in shaping public discourse on these issues.
A separate ruling from the Yargıtay, reported by *TGRT Haber* on March 14, 2026, also highlights Karakaş’s recent commentary. This ruling concerns the ability of banks to place holds on the pensions of retirees who have taken out consumer loans, despite regulations protecting pension funds from seizure except for alimony debts. Karakaş warned that consumer loan agreements often contain waivers allowing banks to circumvent these protections, potentially leaving retirees vulnerable to financial hardship. This demonstrates the breadth of Karakaş’s expertise and his ongoing engagement with critical issues affecting Turkish citizens.
The Yargıtay’s decision regarding smart drug reimbursement is likely to spark further debate about access to healthcare, the role of the state in funding innovative treatments, and the balance between individual rights and collective responsibility. The coming months will be crucial in observing how this ruling is implemented in practice and whether it leads to increased access to appropriate medications for patients in need, or creates new barriers to care.
The next step in this evolving situation will be the SGK’s issuance of updated guidelines for reimbursement requests, reflecting the criteria established by the Yargıtay. These guidelines are expected to be released within the next quarter. We will continue to monitor developments and provide updates as they become available. Share your thoughts on this key ruling in the comments below.
Worth a look